spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  eltrombopag 

 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2014
Aileron Therapeutics Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2014
Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2011
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2010
Ligand Announces Approval for Revolade(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2009
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Mar 2008
FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2007
GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2007
Pivotal Phase III Trial Showed PROMACTA(R) (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
GlaxoSmithKline Demonstrates Progress of Oncology Portfolio; New Data to Be Presented at ASCO 2006
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
eltrombopag
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.